NICE recommends bimekizumab for adults with active ankylosing spondylitis

NICE has recommended bimekizumab (Bimzelx) for adult with active ankylosing spondylitis (AS) – a type of arthritis that causes inflammation in the joints and ligaments of the spine. The treatment is only recommended for patients who do not respond well enough to conventional treatments, such as physiotherapy and non-steroidal anti-inflammatory drugs (NSAIDs). It is also recommended for patients with active non‑radiographic axial spondyloarthritis (nr‑axSpA) with objective signs of inflammation when NSAIDs have not worked well enough or are not tolerated, and for patients whom tumour necrosis factor (TNF)-alpha inhibitors are not suitable. Patients should be assessed after 16 weeks of